European committee for orphan medicinal products provides positive opinion on inovio's application for orphan drug designation for ino-3107

European commission to review and make a final decision, expected late may 2023 plymouth meeting, pa. , april 26, 2023 /prnewswire/ -- inovio (nasdaq: ino), a biotechnology company focused on developing and commercializing dna medicines to help treat and protect people from hpv-related diseases, cancer, and infectious diseases, today announced that the european committee for orphan medicinal products (comp) has provided a positive opinion on inovio's application for orphan drug designation in the european union (eu) for ino-3107.
INO Ratings Summary
INO Quant Ranking